ET IN THE NEWS |
|
|
|
|
The Diann Shaddox Foundation for Essential Tremor is proud to announce the appointment of Bill Hazel as a new DSF Board Trustee.
Bill is a Director at Cedar Wealth Management where the firm focuses helping clients with a variety of Investment advice ranging from retirement funds to Private Investing opportunities. Prior to joining Cedar Wealth Bill was a senior vice president and principal at Eubel Brady & Suttman Asset Management in Dayton, Ohio. Bill’s experience includes managing asset allocation, equity, and alternative strategies for institutional investors including state and local municipalities, retirement and pension funds, educational foundations, endowments and large retail organization.
Bill served on Sinclair Community College Foundation Investment Committee. Vice Chairman for CAMO LLC CAMO a Service-Disabled Veteran-Owned, Small Business (SDVOSB) with headquarters in Beavercreek, Ohio. Bill earned a B.S. in Business Management from Capitol University, member of Rotary International, a Paul Harris Fellow, and supports the Wounded Warriors Foundation and several local charities. Randy Miles Executive Director |
|
Sage & Biogen ET Clinical Trial
About the KINETIC 2 TRIAL. Sage & Biogen are looking for adults ages 18 to 80 years old who have been formally diagnosed with essential tremor for at least three years to take part in the KINETIC 2 TRIAL. The purpose of this study is to evaluate the safety and efficacy of three different doses of an investigational drug compared to a placebo on tremor reduction. A placebo is an inactive pill that looks like the investigational drug but contains no active medication. Participation in the KINETIC 2 TRIAL lasts approximately 19 weeks, including 11 clinic visits and five phone calls from the study team.
Interested individuals will be evaluated to determine their eligibility to participate in this study. Each patient who participates will receive either the investigational drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. To learn more, visit KINETIC2TrialET.com. |
|
Jazz Pharmaceuticals ET Clinical Trial
Would you like to participate in a study for Essential Tremor (ET)?
We are inviting you to take part in a study for adults who experience tremors in an upper limb (such as your arms) due to ET. All study-related visits, tests, and investigational medication will be provided at no cost to you. In addition, reimbursement for time and travel may be provided. No health insurance is required. Jazz Pharmaceuticals Phase 2b Clinical Trial in essential tremor. |
|
Praxis Precision Medicines ET Clinical Trials
PRAXIS PRECISION MEDICINES PROVIDES CORPORATE UPDATE May 9, 2022 at 4:01 PM EDT
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study “This is an incredibly exciting time at Praxis, with recent events bringing us closer to our long-term vision,” said Marcio Souza, president and chief executive officer of Praxis. “With positive topline results from our PRAX-944 Phase 2a study in essential tremor, and plans to accelerate development in the ongoing Essential1 study, we will soon have a second late-stage clinical asset along with a deep and innovative early-stage pipeline. https://www.linkedin.com/company/praxis-precision-medicines-inc/videos/ |
|
Sage is proud to be named one of America’s Most Trusted Companies by Newsweek. We’re committed to shaping the future of #brainhealth and developing medicines that positively impact the lives of our patients.
#ThisIsSage |
|
DSF is proud to announce our continuing partnership with Kroger Company who will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
|
|
DSF is proud to announce our partnership/sponsorship with Sage Therapeutics who will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
|
|
DSF is proud to announce our partnership/sponsorship with Jazz Pharmaceuticals who will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
|
|
DSF is proud to announce our partnership/sponsorship with Sage Therapeutics & Biogen who will help DSF change the future for everyone who will inherit or develop Essential Tremor by offering hope and assistance for people suffering from hardships magnified by Essential Tremor.
|
Barry Greene CEO at Sage Therapeutics
I welcome every opportunity to shine a light on the #brainhealth pandemic and the urgent need for innovation in care. I was thrilled to join #TEDxBoston to discuss how we are working to develop novel therapies to move from brain health awareness to brain health action. Watch my full talk here. |
|
New Treatment Research in the News 2022
Neuroscience News
New MRI Probe Can Reveal More of the Brain’s Inner Workings
Neuroscience News
New MRI Probe Can Reveal More of the Brain’s Inner Workings
JAMA Neurology | Original Investigation
Association of Essential Tremor With Novel Risk Loci
A Genome-Wide Association Study and Meta-analysis
Association of Essential Tremor With Novel Risk Loci
A Genome-Wide Association Study and Meta-analysis
|
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system (“CNS”) disorders characterized by neuronal imbalance.
Praxis is in the process of developing a new medication specifically focused on treating Essential Tremor. |
|
Diann Shaddox Foundation For Essential Tremor is Platinum Transparency for 2022
|
|
DSF ET talksCher Burnham Matteson Board Trustee & Director of Family Assistance on Facebook Live ET Talk event
January 8, 2022. Talking about living with Essential Tremor |
|
Ask Your Legislator to Support an FDA Neuroscience Center of Excellence
Leaders of the Congressional Neuroscience Caucus and the Brain Injury Task Force are circulating a sign-on letter to the Energy & Commerce Committee in support of the creation of a Neuroscience Center of Excellence (NCOE) at the Food and Drug Administration (FDA). A Neuroscience Center of Excellence would help the more than ten million people living with essential tremor by creating a more transparent and patient-focused process at the FDA to speed the delivery of safe and effective treatments to patients.
|
|
millions of faces of et |
|
|
|
|
Diann Shaddox &
Dr. Drew Christensen |
Team DSF ET |
|
Congressman Joe Wilson |
Colen Lindell.
|
|
SIGN UP FOR OUR EMAIL NEWSLETTER AND GET THE LATEST INFO ON EVENTS, FUNDRAISERS AND WAYS TO MAKE AN IMPACT.
|
About DSF | DSF Events | Shop DSF | Contact Us | Terms of Use | Privacy Policy |
Diann Shaddox Foundation for Essential Tremor
Diann Shaddox Foundation for Essential Tremor
© 2014 and beyond | Diann Shaddox foundation ™| All Rights Reserved. No part of this website is public domain.
All contributions are tax deductible to the extent allowable by law.
All contributions are tax deductible to the extent allowable by law.
